<DOC>
	<DOCNO>NCT02393248</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacological activity INCB054828 subject advanced malignancy . This study three part , dose escalation ( Part 1 ) , dose expansion ( Part 2 ) combination therapy ( Part 3 ) .</brief_summary>
	<brief_title>Open-Label , Dose-Escalation Study INCB054828 Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Male female subject , age 18 year old day sign consent 2 . Part 1 : Any advanced solid tumor malignancy ; Part 2 : Subjects squamous nonsmall cell lung cancer , cholangiocarcinoma/gastric cancer , urothelial cancer , breast/endometrial cancer , multiple myeloma , MPNs tumor malignancy evaluate confirmed harbor genetic alteration FGF FGFR gene . A subject 's fibroblast growth factor ( FGF ) fibroblast growth factor receptor ( FGFR ) alteration may base local central laboratory result . Part 3 : Dose finding : subject solid tumor malignancy qualify combo therapy ; doseexpansion : FGF/FGFR+ subject qualify receive combo therapy 3 . Has progress prior therapy effective standard anticancer therapy available ( include subject refuse intolerant ) 4 . Life expectancy &gt; 12 week 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status : Part 1 : 0 1 Part 2 3 : 0 , 1 , 2 1 . Treatment investigational study drug indication reason , receipt anticancer medication within 21 day 5 halflives first dose study drug 2 . Prior receipt selective FGFR inhibitor 3 . History calcium/phosphate homeostasis disorder 4 . History and/or current evidence ectopic mineralization/calcification 5 . Current evidence corneal disorder/keratopathy 6 . Has history presence inadequate liver , renal , hematopoietic and/or cardiac function parameter outside protocoldefined range 7 . Prior radiotherapy within 2 week study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>alteration FGF FGFR</keyword>
	<keyword>squamous non-small cell lung cancer</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>urothelial cancer</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>MPN</keyword>
</DOC>